Pure Global AI
NCT06049134Recruiting

Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy

M.D. Anderson Cancer CenterPhase 4ClinicalTrials.govbiological
Verified
Study focus
Disease/Condition
Lymphoma
Drug/Device/Intervention
PCV20
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
M.D. Anderson Cancer Center
Location
Houston, United States of America
Timeline & enrollment
Phase
Phase 4
Start date
Oct 06, 2023
End date
Jul 31, 2025
Enrollment
30 participants
Primary outcome

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Summary

To compare the effects of a pneumococcal vaccine called PCV20 when given as a single dose
 versus a boosted regimen to patients who previously received anti-CD20 therapy as treatment
 for B cell lymphoma.

ICD-10 classifications
Hodgkin lymphomaFollicular lymphomaNon-Hodgkin lymphoma, unspecifiedFollicular lymphoma, unspecifiedHodgkin lymphoma, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06049134
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06049134 through Pure Global AI's free database. This Phase 4 trial is sponsored by M.D. Anderson Cancer Center and is currently Recruiting. The study focuses on Lymphoma. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.